GET DAILY SIGNALSTreace Medical Concepts (TMCI) Climbs +22% After Q3 Beat and Analyst Upgrades
Key Takeaways
- TMCI shares advanced roughly 22% over the trailing 30 days, climbing from about $3.95 to $4.83.
- The move was fueled by a third-quarter earnings beat, a swing to positive adjusted EBITDA, and two analyst upgrades to Buy.
- Stifel lifted Treace to Buy from Hold with a $6.50 price target, and UBS upgraded the stock to Buy from Neutral.
- Revenue still declined 4% year over year in Q3, but double-digit case-volume growth and improving margins are supporting investor sentiment.
- The broader quarter has been volatile, with shares sliding toward $3.78 in early October before the sharp rebound.
Company Snapshot: Treace Medical Concepts (TMCI)
Treace Medical Concepts, Inc. is a medical technology company focused on advancing the surgical treatment of bunions and related foot and ankle conditions. Its flagship product, the Lapiplasty 3D Bunion Correction System, is designed to correct the bunion deformity in all three planes while securing the unstable joint at its root cause. The company estimates that bunions affect approximately 67 million Americans, with about 1.1 million considered annual surgical candidates.
Beyond Lapiplasty, Treace has built a broader portfolio that includes the Adductoplasty Midfoot Correction System, the Nanoplasty and Percuplasty minimally invasive bunion systems, the SpeedMTP fusion system, the SpeedPlate implant platform, and the IntelliGuide digital planning technology. With a customer base of more than 3,300 surgeons, the company is working to expand from a single-procedure franchise into a comprehensive foot and ankle solutions provider. Investors follow TMCI closely for its procedure-volume growth, new product adoption, and progress toward profitability.
Recent Stock Performance: The Last 30 Days and Quarter
Over the last 30 days, TMCI shares rose approximately 22%, moving from a closing price near $3.95 to about $4.83. The advance accelerated in early November after the company reported third-quarter results and received multiple analyst upgrades. When I reviewed comparable names in the space, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The trailing quarter tells a more uneven story. In early August, the stock traded around $4.70, then drifted lower through September and into early October, touching a low near $3.78 before rebounding. On a net basis, the stock was little changed to modestly higher over the three-month span, but the path was marked by a pronounced V-shaped recovery. The recent rally has therefore been driven more by a sharp reversal in sentiment than by a steady, uninterrupted uptrend.
What Drove the Move in the Last 30 Days
The primary catalyst was Treace's third-quarter 2026 earnings report. Revenue came in at $48.3 million, slightly ahead of the roughly $47.8 million consensus estimate, while the adjusted loss of $0.19 per share beat expectations of a $0.25 loss. Although revenue declined 4% year over year, gross margin improved to 79.5%, the net loss narrowed 23% to $12.6 million, and adjusted EBITDA swung to a positive $0.3 million from a $2.6 million loss a year earlier.
Momentum also came from Wall Street. Stifel upgraded Treace to Buy from Hold and raised its price target to $6.50 from $4.50, citing a "more visibly positive" revenue outlook and improving adjusted EBITDA profitability. UBS separately moved the stock to Buy from Neutral. The company also announced the first surgical cases with its Tailorplasty MIS Tailor's Bunion Correction System, reinforcing its push into adjacent foot and ankle procedures. Double-digit case-volume growth during the quarter further supported the more constructive narrative.
Quarterly Drivers and Transition Story
The quarterly trend has been shaped by Treace's ongoing transition from a Lapiplasty-focused business into a broader bunion and foot-and-ankle platform. Strong case-volume growth and the launch of several new systems, including the minimally invasive Nanoplasty and Percuplasty offerings, have expanded the company's addressable market. However, a product mix shift toward lower-priced systems has pressured average selling prices, keeping reported revenue in modest year-over-year decline even as procedure volumes grow.
Softer consumer sentiment and broader macro conditions have also weighed on elective procedure demand, contributing to the stock's early-quarter weakness. Management's cost-reduction efforts have, in contrast, provided a positive counterweight: operating expenses fell about 10% in Q3, and year-to-date cash usage declined more than half compared with the prior year. That improving profitability trajectory, combined with new product traction, helped lay the foundation for the late-quarter rally.
What to Watch Next for TMCI
Investors will likely monitor whether Treace can return to year-over-year revenue growth, particularly in its seasonally strong fourth quarter. Management narrowed full-year 2026 revenue guidance to a range of $206 million to $210 million and continues to target further reductions in cash usage and progress toward adjusted EBITDA breakeven. Adoption of the newer minimally invasive bunion systems and the Tailorplasty platform will be central to that goal, as will stabilization of the average-selling-price mix.
Additional factors to watch include any further analyst rating or price-target changes, the pace of case-volume growth, elective procedure demand amid broader consumer spending trends, and continued clinical data supporting the Lapiplasty and adjacent platforms. As with any early-stage, still-unprofitable medtech company, execution on profitability and cash flow remains a key swing factor for the stock. From what I see, the improving margin profile stands out as a constructive sign.
Using Tickeron’s AI Tools for Deeper Research
I often turn to Tickeron’s AI Trading Bots when evaluating how automated strategies are positioned around names like this one. The platform lets me review a range of bots across different timeframes and performance metrics, which helps put the recent move in TMCI into broader context without relying solely on manual charting. It is a practical way to cross-check sentiment shifts with data-driven signals before forming a view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TMCI in upward trend: 10-day moving average moved above 50-day moving average on November 02, 2026
The 10-day moving average for TMCI crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +5.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMCI advanced for three days, in 203 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 129 of 162 cases where TMCI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMCI moved out of overbought territory on October 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 24 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TMCI as a result. In 78 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
The Moving Average Convergence Divergence Histogram (MACD) for TMCI turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 39 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 87%.
TMCI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMCI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TMCI broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.869) is normal, around the industry mean (4.142). P/E Ratio (-4.380) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.430) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. TMCI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMCI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement